NICE

The OHE gave the following presentations at ISPOR 17th Annual European Congress in Amsterdam, The Netherlands.

The OHE presented the following posters at ISPOR 17th Annual European Congress in Amsterdam, The Netherlands.

ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. This is the second of two blog posts that outlines OHE’s involvement. (The first blog is available...

ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. OHE’s Adrian Towse is current President of ISPOR and involved in several sessions. Important research on a range of topics will be...

OHE long has been involved in analysing the nature of innovation and the effects of regulation. Two recent OHE presentations address the core issues.

OHE’s active involvement in a number of recent conferences and meetings has contributed to discussions on a range of important issue in health economics.

Just out is a new Research Paper from OHE that examines how local NHS organisations in Wales adjust spending to accommodate ‘shocks’ such as new NICE mandates for covering specific technologies. By law, technologies recommended by NICE are to be funded within three months of publication of NICE’s technology appraisal (TA) decision.

This recent research is intended to inform changes in NICE's approach to assessing the value of medical technologies.
Throughout the year, OHE presents a number of Lunchtime Seminars intended to discuss important current issues in health economics. On 30 January, OHE invited Dr Donna Rowen of the University of Sheffield to present her recent research on defining social preferences.

This paper counters recent research that recommended NICE lower its threshold from the current official £20,000-£30,000.

Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold

The OHE has just published an Occasional Paper by Barnsley et al that counters the recently-published recommendation by Claxton et all that NICE should lower its cost-per-QALY threshold from the current £20,000–£30,000 official range to £12,936. The Claxton et al paper is an excellent attempt at answering a difficult question, based on a detailed analysis of differences in spending and mortality across Primary Care Trusts (PCTs) throughout England during the 2008–09 financial year.

Using data for 1999-2011, this thorough analysis explores what has most influenced NICE's decisions and whether this has changed.

Established in 1999, the National Institute for Health and Care Excellence (NICE) undertakes appraisals of selected technologies and issues guidance intended to ensure quality and value for money. Its decisions are binding within the NHS and also affect decisions by health technology assessment bodies and payers in other countries.

Pages

Subscribe to RSS - NICE